What is Axol Bioscience?
Axol Bioscience specializes in providing human cell culture systems and custom services tailored for disease modeling and drug discovery. Their offerings are crucial for researchers and pharmaceutical companies seeking to develop new therapies and understand complex biological mechanisms. By supplying advanced cell culture solutions, Axol Bioscience plays a vital role in accelerating the preclinical stages of drug development and enhancing the accuracy of disease research.
How much funding has Axol Bioscience raised?
Axol Bioscience has raised a total of $8.8M across 3 funding rounds:
Angel/Seed
$1.4M
Unspecified
$3.2M
Unspecified
$4.2M
Angel/Seed (2016): $1.4M, investors not publicly disclosed
Unspecified (2017): $3.2M led by Calculus Capital
Unspecified (2022): $4.2M supported by Scottish Enterprise, Calculus Capital, and Par Equity
Key Investors in Axol Bioscience
Calculus Capital
Calculus Capital is a UK-based investment manager focused on providing tax-efficient growth capital to smaller companies, particularly in high-growth technology, healthcare, and creative industries.
Scottish Enterprise
Scottish Enterprise is the national economic development agency of the Scottish Government, dedicated to supporting businesses and driving economic growth within Scotland.
Par Equity
Par Equity USA LLC operates within the investment banking sector, reportedly based in Edinburgh, South Australia, Australia, and focuses on investment activities.
What's next for Axol Bioscience?
The recent major strategic investment positions Axol Bioscience for an accelerated growth trajectory. With enterprise-level backing, the company is poised to expand its service offerings, enhance its technological capabilities, and potentially broaden its market reach. This infusion of capital will likely fuel further innovation in cell culture technology, supporting advancements in personalized medicine and the development of novel therapeutics. The strategic nature of the investment suggests a focus on synergistic partnerships and market consolidation within the drug discovery ecosystem.
See full Axol Bioscience company page
